Suggested remit - To appraise the clinical and cost effectiveness of mexiletine within its marketing authorisation for treating myotonia in adults with non-dystrophic myotonic disorders.
 
Status In progress
Process STA 2018
ID number 1488

Provisional Schedule

Expected publication 12 August 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Lupin Healthcare (mexiletine)
Others Department of Health and Social Care
  NHS East and North Hertfordshire CCG
  NHS England
  NHS Southern Derbyshire CCG
  Welsh Government
Patient carer groups Arthritis & musculoskeletal Alliance
  Disability Rights UK
  Genetic Alliance UK
  Leonard Cheshire Disability
  Muscular Dystrophy UK
  Muslim Council of Britain
  Myotonic Dystrophy Support Group
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of British Neurologists
  Association of Genetic Nurses & Counsellors
  British Heart Rhythm Society
  British Institute of Musculoskeletal Medicine
  British Myology Society
  British Orthopaedic Association
  British Society for Genetic Medicine
  British Society of Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Primary Care Respiratory Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association

Commentators

Associated public health groups National Congenital Anomaly and Rare Disease Registration Service, Public Health England
  Public Health England
  Public Health Wales
Comparator companies Accord Healthcare Limited
  Aurobindo Pharma – Milpharm Ltd
  GlaxoSmithKline UK
  Mylan
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Cystic Fibrosis and Genetic Disorders Group
  Cochrane Musculoskeletal Group
  Genomics England
  John Walton Muscular Dystrophy Research Centre
  MRC Centre for Neuromuscular Diseases
  MRC Clinical Trials Unit
  North Star Clinical Network
  National Institute for Health Research
  TREAT-NMD

Timeline

Key events during the development of the guidance:

Date Update
23 September 2019 Invitation to participate
23 September 2019 In progress, Invitation to Participate
04 June 2019 Committee meeting: 1
23 January 2019 (10:00) Scoping workshop (London)
19 November 2018 - 17 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 1488

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance